Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles
about
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseHuman CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificityMolecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidateHistorical Perspectives on Flavivirus ResearchUtility, limitations, and future of non-human primates for dengue research and vaccine developmentThe human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsSafety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studyInduction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccineDeveloping a dengue vaccine: progress and future challenges.T cell immunity to dengue virus and implications for vaccine design.Vaccines licensed and in clinical trials for the prevention of dengue.Immunopathogenesis Versus Protection in Dengue Virus Infections.
P2860
Q26700078-A50165DD-F3B6-407C-A55F-9BE0603B09F9Q27014663-08C9CAC4-1D35-4235-9554-CA1F5B10F3FFQ28733418-84CAA37A-4F33-4A24-ACB4-F141C920F703Q29587283-C3D58104-F3FD-40DD-A571-92B30DCC268AQ29994534-068D59B6-202F-48D8-8143-4CD32D906DFAQ34238916-44507E92-FDFB-4827-8D68-8C63C555A7AFQ34992520-C18DD63F-E5C2-4034-A2A3-B773471A0E44Q35886539-4710AC3C-D985-4794-B063-BD6DB34F426CQ36181531-F239FBB7-00E8-4270-B029-F033F2B74D69Q36288109-E93B1C6D-9E4E-46C2-A6BF-41E79253BEE0Q37500519-0F80F813-FA80-4F61-BCE5-90394DCF580CQ38201151-52B660E4-AB3A-49C5-A08C-0331A246866AQ38631171-59BD5B26-DF29-4D77-B1C9-70D1AA1BCDBCQ39172722-98E6155E-0E8B-4B89-9711-E5A366741609Q39410861-D18DB656-FFA1-47F8-AF97-670BD5628ECE
P2860
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccination of volunteers with ...... nologic and virologic profiles
@en
Vaccination of volunteers with ...... ologic and virologic profiles.
@nl
type
label
Vaccination of volunteers with ...... nologic and virologic profiles
@en
Vaccination of volunteers with ...... ologic and virologic profiles.
@nl
prefLabel
Vaccination of volunteers with ...... nologic and virologic profiles
@en
Vaccination of volunteers with ...... ologic and virologic profiles.
@nl
P2093
P2860
P50
P921
P1433
P1476
Vaccination of volunteers with ...... nologic and virologic profiles
@en
P2093
Beth D Kirkpatrick
Kristen K Pierce
Marya P Carmolli
P2860
P304
P356
10.1016/J.VACCINE.2013.05.075
P407
P577
2013-06-02T00:00:00Z